Drug intelligence / Profile preview

Cytraben

Development stage
Unknown
Lead developer
Arian Salamat Sina
Modality
Small Molecules
Administration
Oral
01

Overview

Cytraben (also marketed as Citrabone) is a consumer dietary supplement developed and manufactured by Arian Salamat Sina in collaboration with Holistica Laboratories. It is formulated to support bone and joint health, prevent osteoporosis, and maintain bone density, particularly in postmenopausal women, elderly individuals, and those with calcium deficiencies. The supplement contains calcium citrate, which offers superior absorption compared to calcium carbonate and does not require an acidic stomach environment, making it highly suitable for individuals taking antacids or those with low stomach acid. It is co-formulated with marine magnesium, which supports muscle function and calcium metabolism, and natural vitamin D3 (cholecalciferol) to optimize calcium absorption.

Brand names
CitrabenCitraboneCytraben
Other names
calcium citrate + magnesium + cholecalciferolcalcium citrate + magnesium + vitamin D3
02

Targets

CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Cytraben.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytraben.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call